Literature DB >> 18684941

Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.

Monika Kasprzycka1, Qian Zhang, Agnieszka Witkiewicz, Michal Marzec, Magdalena Potoczek, Xiaobin Liu, Hong Yi Wang, Michael Milone, Samik Basu, Joanne Mauger, John K Choi, J Todd Abrams, J Steven Hou, Alain H Rook, Eric Vonderheid, Anders Woetmann, Niels Odum, Mariusz A Wasik.   

Abstract

In this study, we demonstrate that malignant mature CD4(+) T lymphocytes derived from cutaneous T cell lymphomas (CTCL) variably display some aspects of the T regulatory phenotype. Whereas seven cell lines representing a spectrum of primary cutaneous T cell lymphoproliferative disorders expressed CD25 and TGF-beta, the expression of FOXP3 and, to a lesser degree, IL-10 was restricted to two CTCL cell lines that are dependent on exogenous IL-2. IL-2, IL-15, and IL-21, all of which signals through receptors containing the common gamma chain, induced expression of IL-10 in the IL-2-dependent cell lines as well as primary leukemic CTCL cells. However, only IL-2 and IL-15, but not IL-21, induced expression of FOXP3. The IL-2-triggered induction of IL-10 and FOXP3 expression occurred by signaling through STAT3 and STAT5, respectively. Immunohistochemical analysis of the CTCL tissues revealed that FOXP3-expressing cells were common among the CD7-negative enlarged atypical and small lymphocytes at the early skin patch and plaque stages. Their frequency was profoundly diminished at the tumor stage and in the CTCL lymph node lesions with or without large cell transformation. These results indicate that the T regulatory cell features are induced in CTCL T cells by common gamma chain signaling cytokines such as IL-2 and do not represent a fully predetermined, constitutive phenotype independent of the local environmental stimuli to which these malignant mature CD4(+) T cells become exposed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684941      PMCID: PMC2586884          DOI: 10.4049/jimmunol.181.4.2506

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Nonredundant roles for Stat5a/b in directly regulating Foxp3.

Authors:  Zhengju Yao; Yuka Kanno; Marc Kerenyi; Geoffrey Stephens; Lydia Durant; Wendy T Watford; Arian Laurence; Gertraud W Robinson; Ethan M Shevach; Richard Moriggl; Lothar Hennighausen; Changyou Wu; John J O'Shea
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

2.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

3.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.

Authors:  Masahiro Ono; Hiroko Yaguchi; Naganari Ohkura; Issay Kitabayashi; Yuko Nagamura; Takashi Nomura; Yoshiki Miyachi; Toshihiko Tsukada; Shimon Sakaguchi
Journal:  Nature       Date:  2007-03-21       Impact factor: 49.962

4.  IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

Authors:  Matthew A Burchill; Jianying Yang; Christine Vogtenhuber; Bruce R Blazar; Michael A Farrar
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

5.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Authors:  Monika Kasprzycka; Michal Marzec; Xiaobin Liu; Qian Zhang; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

6.  Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency.

Authors:  Aileen C Cohen; Kari C Nadeau; Wenwei Tu; Vivian Hwa; Kira Dionis; Liliana Bezrodnik; Alejandro Teper; Maria Gaillard; Juan Heinrich; Alan M Krensky; Ron G Rosenfeld; David B Lewis
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 7.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Authors:  Thomas A Waldmann
Journal:  Nat Rev Immunol       Date:  2006-08       Impact factor: 53.106

8.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

Authors:  Marc A Gavin; Troy R Torgerson; Evan Houston; Paul DeRoos; William Y Ho; Asbjørg Stray-Pedersen; Elizabeth L Ocheltree; Philip D Greenberg; Hans D Ochs; Alexander Y Rudensky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

9.  FOXP3 controls regulatory T cell function through cooperation with NFAT.

Authors:  Yongqing Wu; Madhuri Borde; Vigo Heissmeyer; Markus Feuerer; Ariya D Lapan; James C Stroud; Darren L Bates; Liang Guo; Aidong Han; Steven F Ziegler; Diane Mathis; Christophe Benoist; Lin Chen; Anjana Rao
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

10.  Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.

Authors:  Machteld M Tiemessen; Tracey J Mitchell; Lisa Hendry; Sean J Whittaker; Leonie S Taams; Susan John
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

View more
  27 in total

Review 1.  NFκB function and regulation in cutaneous T-cell lymphoma.

Authors:  Tzu-Pei Chang; Ivana Vancurova
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

2.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

3.  Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Authors:  Qian Zhang; Hongyi Wang; Kanchan Kantekure; Jennifer C Paterson; Xiaobin Liu; Andras Schaffer; Chrystal Paulos; Michael C Milone; Niels Odum; Suzanne Turner; Teresa Marafioti; Mariusz A Wasik
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

4.  Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.

Authors:  Tzu-Pei Chang; Vladimir Poltoratsky; Ivana Vancurova
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

5.  The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Authors:  Ce Tiffon; Je Adams; L van der Fits; S Wen; Pa Townsend; A Ganesan; E Hodges; Mh Vermeer; G Packham
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 6.  The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Ronnie M Abraham; Qian Zhang; Niels Odum; Mariusz A Wasik
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

7.  Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Authors:  Qian Zhang; Hong Yi Wang; Fang Wei; Xiaobin Liu; Jennifer C Paterson; Darshan Roy; Daniela Mihova; Anders Woetmann; Andrzej Ptasznik; Niels Odum; Stephen J Schuster; Teresa Marafioti; James L Riley; Mariusz A Wasik
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

8.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

9.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

10.  Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.

Authors:  De-Kuan Chang; Jianhua Sui; Shusheng Geng; Asli Muvaffak; Mei Bai; Robert C Fuhlbrigge; Agnes Lo; Anuradha Yammanuru; Luke Hubbard; Jared Sheehan; James J Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  Mol Cancer Ther       Date:  2012-08-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.